Rebecca Kristeleit

Rebecca Kristeleit is a medical oncologist who has been an investigator on multiple PARP inhibitor trials including ARIEL3 (rucaparib) and has contributed to analyses specifically examining outcomes in primary peritoneal carcinoma patients within ovarian cancer trial populations. She has published on PARP inhibitor use in the recurrent setting and the relationship between HRD status and response in peritoneal carcinoma. She also investigates folate receptor alpha-directed therapy with mirvetuximab soravtansine in platinum-resistant disease.